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CASE REPORT
INTRODUCTION
Cholestasis refers to a condition of decreased or ab-
sence of bile flow into the duodenum due to intra-he-
patic or extra-hepatic abnormalities. The intra-hepatic
abnormalities are localized in the hepatocyte or intra-
hepatic bile duct. Intra-hepatic cholestasis can be he-
reditary, as in the case of benign recurrent intra-hepatic
cholestasis, Dubin-Johnson syndrome, Rotor syndrome,
and porfiria; or acquired, such as in the case of drug-
induced cholestasis, or that due to infection, alcohol, to-
tal parenteral nutrition, etc. The clinical cholestatic syn-
drome manifests in the form of jaundice, pruritus, in-
creased blood bilirubin, and increased alkaline phos-
phatase and bile acid.1,2
Benign recurrent intrahepatic cholestasis (BRIC) or
idiopathic recurrent intrahepatic cholestasis is a rare syn-
drome of recurring cholestasis that is usually familial and
autosomal recessive. This disorder could be found in ages
8 months to 60 years, and 75% manifests in an age of
less than 20 years. The male to female ratio is 1.7:1.1,2,3,4
The etiology of BRIC is still unknown. However, re-
search shows that patients with a predisposition for BRIC
have decreased primary bile acids cholate and
chenodeoxycholate, and increased secondary bile acids
lithocholate and deoxycholate, which are more
cholestatic. A high fat diet and colon infection could cause
increased toxic secondary bile acids due to fat malab-
sorption and bacterial metabolism in the colon. Environ-
mental factors could also disturb bile acid metabolism
and bile secretion through allergic or hypersensitivity
reaction, even though the mechanism is still unclear.3,4
The clinical characteristic of BRIC is recurring
cholestasis usually proceded by pruritus, constitutional
symptoms such as weakness, decreased appetite, weight
loss and influenza-like symptoms for 2 to 4 weeks.1,3,4
The patient also commonly complains of nausea and
vomiting, sometimes also abdominal discomfort and whit-
ish defecation.1,3 Attacks of jaundice usually last for 1 to
4 months and then resolve spontaneously. The next at-
tack recurs within 1 month to 20 years, and between
attacks the patient is normal and has no complaints.1,3,4,5,6
Such attacks could recur for a lifetime. There has been
a report of a patient who suffered from 27 attacks in 38
years.3 The first attack of jaundice could be induced by
pregnancy or the use of oral contraception such as me-
thyl-testosteron or other steroids. However, in establish-
ing the diagnosis of BRIC, the influence of drugs and
pregnancy are annulled, since intrahepatic cholestasis
of pregnancy and drug-induced intrahepatic cholestasis
are separate diagnostic entities.4
Laboratory results demonstrate severely increased
direct billirubin, increased indirect billirubin, positive uri-
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nary billirubin, increased serum alkaline phosphatase,
usually normal serum gamma-glutamil transferase (GT),
and mildly increased or normal serum transaminase.1,3
Liver biopsy demonstrates cholestasis in the form of ac-
cumulated bile pigment or bile plug Summerskill-Tygstrup
in the hepatocytes and bile canals, infiltration of the por-
tal ducts by mononuclear cells and sometimes eosino-
phils, and sometimes there is mild fibrosis in the periph-
eral and centrilobar zones (zone 1 and 3).1,3,4,7 The mor-
phology of liver biopsy is not patognomonic since it could
resemble other intrahepatic cholestasis. Outside of at-
tacks, laboratory and histologic findings of the liver are
normal.
Cholangiography and ultrasonographic examination
do not show signs of obstruction. Another supporting
examination is the examination of the 18th chromosome,
which demonstrate an abnormal locus on the q21-22
position of the long arm, as also found in Byler syndrome
and progressive familial intrahepatic cholestasis 1
(PFIC1), which signifies a protein defect that disturbs
bile acid transport.1,8,9,10
Summerskill-Tygstrup et al formulated the following
criteria for benign recurrent intrahepatic cholestasis:4
1. Recurrent attacks of jaundice accompanied by se-
vere pruritus and cholestasis based on biochemical
examination.
2. The presence of bile plugs in liver biopsy.
3. Normal intra and extrahepatic bile duct based on
cholangiography.
4. Absence of other factors that could cause intrahe-
patic cholestasis, such as pregnancy and drugs.
5. Periods of absence of symptoms for months or years.
Intrahepatic cholestasis is called benign because long-
term examination does not reveal fibrosis, cirrhocis or
liver failure.4,7
Therapy for BRIC is still unclear. Therapy is usu-
ally symptomatic, such as to alleviate the itch and com-
bat infection with antibiotics. Several medications in re-
search to deal with pruritus are as follows:1,3
• Cholestiramine: 12-16 g/day
• Ursodeoxycholic acid: 13-15 mg/kg bodyweight/day
• Antihistamine: hydroxyzine and difenhydramine, es-
pecially for nocturnal pruritus.
• Rifampisin: 300-600 mg/day
There is yet a sure therapy for the cholestasis itself.
A medication commonly used is ursodeoxycholic acid,
which reduces destruction of hepatic cells due to accu-
mulation of toxic bile acid that obstructs the secretion of
bile acids. The process of bile secretion and intrahepatic
cholestasis also involves cellular mechanisms such as
cellular immunity, which could explain how corticoster-
oid therapy may be able to help reduce cholestasis.3 Other
medications that could reduce intrahepatic cholestasis
but still require further research are azatioprin,
chlorambucyl, cholchicine, cyclosporine, S-
adenosylmethionine, FK 506 and methotrexate.
CASE ILLUSTRATION
Mrs. N, 35 years, a middle-class housewife, was
hospitalized on the fifth floor of IRNA B (B ward) of
the Cipto Mangunkusumo Hospital from the 23rd to the
29th of August 2000, with a chief complaint of yellowish
color all over the body from 3 weeks prior to admission.
The yellowish color occurred suddenly, preceded by se-
vere continuous itching and weakness of the whole body.
The patient did not complain of fever nausea, vomiting,
abdominal discomfort, gassiness or diarrhea, and her
appetite was still normal. Her urine was tea-colored, her
defecation was white color. The patient was admitted to
Koja hospital for 10 days, and underwent ultrasound
examination, which proved to be normal, and the patient
was referred to Cipto Mangunkusumo Hospital. For 3
days prior to admission the patient complained of a sore
throat and cough without sputum.
For 7 years prior to admission, the patient had suf-
fered from similar attacks of jaundice 7 times, and the
complaints usually resolve spontaneously after 1 to 3
months. The first attack of jaundice occurred 6 months
after the patient gave birth to her second child and re-
ceived oral contraception. The patient used Microgynon
and stopped taking it every time she suffered from jaun-
dice. The patient had been hospitalized in the Islamic
Hospital of North Jakarta 4 times and twice at the Koja
Hospital, and during three hospitalizations was diagnosed
with cholecystitis and hepatitis, and the rest of the time
no abnormality was found. During hospitalization the
patient usually received Urdafalk, Methicol, Cursil, and
Antacid. The patient also underwent frequent ultrasound
examination and has undergone barium meal and ERCP
examination during attacks, without any abnormal find-
ings. History of other medications was denied. Prior to
attacks the patient often ate fatty foods such as liver,
spleen, etc, but the patient has ceased to do so. The
attacks were not induced by fatty foods. The patient
had a history of transfusion during her third hospitaliza-
tion. The patient suffered from jaundice and fever at the
age of approximately 12 years.
History of bile stone, renal stone, hypertension, dia-
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betes mellitus and pulmonary disease was eliminated.
The patient’s mother has also suffered from jaundice.
Physical examination revealed the patient to be in
good health, soundly alert, with a blood pressure of 120/
70 mmHg, pulse rate of 78 times per minute, respiration
rate of 16 times per minute, temperature of 37oC, body
weight 60 kg and height 158 cm with jaundice in skin,
signs of excoriation due to scratching, and jaundice of
the sclera. The patient’s conjunctiva were not anemic,
her pharynx was hyperemic, her tonsils were T1-T1, her
lymph nodes were not palpable and her jugular venous
pressure was not increased. Heart and lung examina-
tion were within normal limits. Abdominal examination
proved to be soft, liver and spleen were not palpable,
there was no tenderness or ascites, normal positive di-
gestive sounds, and the extremities were warm, there
was no edema or palmar erithema.
Laboratory findings in Koja Hospital of 2nd August
2000 revealed Hemoglobin level of 11.6 g/dl, leukocyte
10,500/ul, Hematocryte 32%, Platelet count 387,000/ul,
LED 63 mm/hour, leukocyte differential count 0/2/0/78/
17/3, billirubin urinalysis 3+, urine urobillinogen 1, other
results were within normal limits. Laboratory findings
on the 18th of August revealed total billirubin of 27.51
mg/dl, direct billirubin of 20.55 mg/dl, and indirect billirubin
of 6.96 mg/dl, SGOT of 39 U/l, SGPT of 41 U/l, albumin
of 3.87 g/dl, globulin of 3.06 g/dl, alkaline phosphatase of
583 U/l and GGT of 11 U, negative HbsAg, negative
IgM anti-HAV, and negative Anti-Hbs. Laboratory tests
over the past years demonstrated billirubin levels rang-
ing from 6 to 17 mg/dl and normal or mildly alleviated
SGOT/SGPT. ERCP at the Islamic Hospital of North
Jakarta in the year 1998 demonstrated obstruction and
stone in the billiary system. Her last ultrasound on the
2nd of August 2000 at the Koja Hospital demonstrated
no obstruction or stone in the billiary system.
The problem in this patient was benign recurrent in-
trahepatic cholestasis and acute pharyngitis. The patient
then underwent complete peripheral blood check, and
hemostasis examination; total, direct and indirect billirubin
measurement; measurement of other liver functions,
ANA and liver biopsy. The patient also received
ursodeoxycholic acid with a dose of 3 x 250 mg, ampicil-
lin-sulbactam 2 x 375 mg and vitamin B complex 3 x 1
tablet and termination of oral contraception.
Repeat laboratory results are as follows: Hemoglo-
bin level 10.1 g/dl, leukocyte 12,400/ul, Hematocryte 31%,
Platelet count 410,000/ul, reticulocyte 11%, total billirubin
21.8 mg/dl, direct billirubin 16.7 mg/dl, SGOT 41 U/l,
SGPT 34 U/l, BT 2 minutes and 30 seconds, CT 13 min-
utes, PT 11.1 (12.8), APTT 35.9 (35.3) and negative
ANA. Biopsy findings demonstrated PA in the form of
hard intra-cell and intra-canal cholestasis (see figure 1.),
almost normal portal, and no significant abnormality be-
tween attacks, which are in accordance with the char-
acteristics of benign recurrent intrahepatic cholestasis.
The patient was then permitted to go home and was
advised to return to the hospital immediately if the jaun-
dice increased, there was fever or abdominal discom-
fort.
The following week, the patient still suffered from
jaundice, but her pharyngitis had resolved. The patient
received ursodeoxycholic acid with a dose of 3 x 250
mg, cholestiramine 3 x 5 g (1 sachet) for only 2 days,
ferrum supplements and 50 mg of prednisone (4-3-3 tab-
lets) per day for 2 weeks which was tapered-off as the
patient’s clinical condition improved. Temporary billirubin
level had reduced. Within 2 months the jaundice resolved
together with other complaints, with a final total and di-
rect billirubin level of 1.0 g/dl and 0.8 g/dl.
DISCUSSION
This is a rare case of cholestasis.4 The intrahepatic
cholestasis in this patient was established as a case of
benign recurrent intrahepatic cholestasis based on an age
of 35 years with recurrent jaundice 7 times in 7 years,
that occured for 1 to 3 months with spontaneous resolu-
tion, accompanied by severe itching, white defecation,
tea-colored urine, history of oral contraception for 7 and
a half years, and family history of mother with jaundice.
These symptoms are in accordance with BRIC, which
inflicts young adults with recurrent jaundice for 1 to 4
months, spontaneous resolution, recurring within an in-
terval of 1 month-20 years accompanied by severe itch-
Figure 1. The picture of hispathology showed the form of
hard intra-cell and intra-canal cholestasis.
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ing, white defecation, tea-colored urine and family his-
tory.1,3,4,5,6
Oral contraception could initially induce attacks, but
recurrent drug-induced cholestasis is not an appropriate
diagnosis for this patient because in patients with drug-
induced cholestasis, jaundice would resolve immediately
after administration of the drug in question is terminated,
while in this patient, jaundice could recur and resolve
any time, independent of the use of oral contraception.1,4
The symptom of sore throat and cough could be a
part of the BRIC syndrome, but a hyperemic pharynx
and leukocytosis signifies a separate problem of acute
bacterial pharingitis.
The diagnosis of BRIC is also supported by increased
total and direct billirubin level, increased alkaline phos-
phatase, normal GGT and normal intra and extra hepatic
findings based on ultrasound examination and cholang-
iography. Liver biopsy demonstrated hard intracellular
and intra-canal cholestasis that most probably signifies
the Summerskill-Tygstrup bile plug, characteristic of but
not patognomonic for BRIC. Symptoms and signs of the
patient’s illness fulfill the criteria for benign recurrent
intrahepatic cholestasis based on Summerskill-Tygstrup.4
Another examination to establish the diagnosis of
BRIC is examination of the 18th chromosome,1,8 which
has not been performed due to impracticality and high-
cost.
The patient received therapy to reduce itching, which
was ursodeoxycholic acid and cholestiramine. The pa-
tient discontinued cholestiramine due to severely disturb-
ing nausea.1,3 The patient received antibiotics to deal with
acute bacterial pharyngitis, also to anticipate signs of
cholangitis, even though such cases are very rare. Such
therapy does not require further hospitalization. The pa-
tient also received an immunosuppressive dose of corti-
costeroid, since BRIC is considered to be related to com-
plex cellular responses of the bile system, even though
this has not been established through research findings.3,4
The patient had been hospitalized 7 times prior to this
one. This is definitely not cost-effective. If biopsy had
been done earlier, the patient would not have spent as
much on hospital care and examinations.
The patient should also receive adequate information
on her disorder, which could recur any time. She should
avoid any possible factors that could induce jaundice,
and she should know the complications of her disorder,
such as cholangitis, even though this rarely occurs. The
patient is also advised to use other methods of contra-
ception, such as IUD or sterilization.
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